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ABSTRACT: Herein, we report the synthesis and neuroprotective power
of some N-substituted C-(dialkoxy)phosphorylated nitrones 4a−g, by
studying their ability to increase the cell viability, as well as their capacity
to reduce necrosis and apoptosis. We have identified (Z)-N-tert-butyl-1-
(diethoxyphosphoryl)methanimine oxide (4e) as the most potent,
nontoxic, and neuroprotective agent, with a high activity against neuronal
necrotic cell death, a result that correlates very well with its great capacity
for the inhibition of the superoxide production (72%), as well as with the
inhibition of lipid peroxidation (62%), and the 5-lipoxygenase activity
(45%) at 100 μM concentrations. Thus, nitrone 4e could be a convenient
promising compound for further investigation.
1. INTRODUCTION
Reactive oxygen species (ROSs) exert their physical functions
at low to moderate concentrations, but at high concentrations,
they become toxic for the living systems, resulting in oxidative
stress (OS).1 Oxidative stress (OS) plays a key role in many
pathologies, being possibly the most important molecular
event occurring before and after ischemic damage.2 Aerobic
organisms have integrated antioxidant systems, which include
enzymatic and nonenzymatic antioxidants that are usually
effective in blocking harmful effects of ROS.3
In this context, free radical scavengers, such as nitrones like
NXY-059 (1) (Figure 1) (Cerovive, AstraZeneca),4,5 are
efficient neuroprotective agents in experimental ischemia
studies.4 However, as NXY-059 (1) failed in advanced clinical
trials for stroke, the neuroprotection therapy strategy for
cerebral ischemia based on antioxidants and nitrone ROS
scavenging agents has been critically analyzed and almost
discontinued.6
In spite of this, the impressive results that we have recently
published using novel quinolylnitrones mean that the structure
and functional groups incorporated in the nitrone cores have a
critical influence on their antioxidant and pharmacological
properties7 and that there is still place for novelty and
originality in this area of medicinal chemistry. On the other
hand, as the capability of phosphorylated nitrones DEPMPO
28 and 2-(diethoxyphosphoryl)-N-(benzylidene)propan-2-
amine oxide derivatives 39 (Figure 1) to trap various radicals
has been well recognized, all of these observations inspired us
to study the antioxidant properties of the N-substituted C-
dialkoxyphosphorylated nitrones 4a−g, including the
(diethoxyphosphoryl)nitrones (DEOPNs) 4a−e and
(dibenzyloxyphosphoryl)nitrones (DBOPNs) 4f,g (Figure 1),
and their neuroprotective properties.
2. RESULTS AND DISCUSSION
2.1. Chemistry. The phosphorylated nitrones 4a−d were
synthesized from hydroxymethylphosphonate (5) by Swern
oxidation and subsequent reaction with the respective
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hydroxylamine10−12 (Scheme 1), whereas nitrones 4e and 4f,g
have been synthesized here for the first time in an analogous
manner starting from diethyl hydroxymethylphosphonate (5)
and dibenzyl hydroxymethylphosphonate (6), respectively
(Supporting Information). According to our previous obser-
vations, crystalline DEOPN 4a exists as a Z isomer, whereas in
chloroform-d as well as in benzene-d6 solutions at room
temperature, a 15:85 equilibrium mixture of E/Z isomers was
noticed (1H NMR analysis).10 Similarly, DEOPN 4b exists as a
14:86 mixture of E/Z isomers.10 On the other hand, both (R)-
and (S)-configured DEOPNs 4c and 4d in chloroform-d
solution form 7:93 mixtures of E/Z isomers.11 Nitrones 4f and
4g in deuterated chloroform solutions form equilibrium
mixtures of E/Z isomers, 10:90 and 5:95, respectively, whereas
nitrone 4e exists as only a Z isomer. Surprisingly, all of the
phosphorylated nitrones 4a−g exist as Z isomers in dimethyl
sulfoxide (DMSO) and less than 2% of E-isomers could be
detected with a 600 MHz NMR spectrometer.
2.2. Neuroprotective Effect of N-Substituted C-
Dialkoxyphosphorylated Nitrones. Following the usual
protocols (see the Supporting Information), we obtained the
cell viability and neuroprotection values shown in Table 1 and
Figure 2. Based on these results, we conclude that all of the
nitrones showed moderate neuroprotective values, in the
micromolar range, from 10.62 (4e) to 131.21 (4c). Second, by
comparing with the EC50 determined for the standard
compounds α-phenyl-tert-butyl nitrone (PBN), citicoline
(CCh), and N-acetyl-cysteine (NAC), it is clear that most of
the nitrones 4, with the exception of 4a and 4c, are more
neuroprotective than PBN and CCh but less than NAC.
Among the DEOPNs 4a−e, on going from nitrone 4a (R =
Me, EC50 = 98.30 μM) to nitrones 4b or 4e, the incorporation
of benzyl or t-butyl motifs, respectively, instead of the methyl
group, produces strong positive neuroprotective responses,
affording the two most neuroprotective agents discovered in
this work. Very interestingly, the α-substitution on nitrone 4b
by a methyl group significantly decreases the neuroprotection
observed for this nitrone, more strongly in the (R)-enantiomer
4c than in the (S)-enantiomer 4d. However, nitrones 4b and
(S)-4d have a lower maximal activity than (R)-4c, which shows
a lower neuroprotection. This is possibly due to the fact that at
high concentrations both nitrones are more toxic than (R)-4c.
This result is very interesting, showing that the absolute
configuration at the stereogenic center has an influence on the
neuroprotection, but unfortunately we have no explanation for
this fact.
This could also be supported by the results of the effect of
these nitrones on the necrotic and apoptotic cell death tests
(Figure 3a,b, see below). By comparing DEOPNs 4a,b with the
corresponding DBOPNs 4f,g, we conclude that nitrone 4f is
2.2-fold more potent than nitrone 4a (P < 0.01) but that
nitrone 4b has a neuroprotective potency very similar to that of
nitrone 4g (nonstatistically significant). However, DBOPNs
4f,g have a maximal neuroprotective effect higher than those of
their corresponding DEOPNs 4a,b, indicating that the addition
of a benzyloxy group, instead of an ethoxy group, affords less
toxicity at high concentration.
To shed light on the neuroprotective effects of nitrones 4a−
g, the effect of these compounds on necrotic and apoptotic
cellular death was measured by monitoring lactate dehydrogen-
Figure 1. Structures of compounds 1−3 and of the (diethoxyphosphoryl)nitrones (DEOPNs) 4a−e and (dibenzyloxyphosphoryl)nitrones
(DBOPNs) 4f,g investigated in this work.
Scheme 1. Synthesis of Nitrones 4a−g
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ase (LDH) release (necrosis) and caspase-3 activity
(apoptosis) from the cultured human neuroblastoma cells.
Results from Figure 3 show that exposure of SHSY5Y
cultures to 4 h OGD (OGD4h) followed by 24 h reperfusion
(R24h) induced a significant increase in LDH release (3.78 ±
0.48%, about 4-fold of the control values; P < 0.001, Student’s
t-test) (Figure 3A). These increasing LDH release values
correlate with the loss in cell viability observed under this
condition (about 35%). Exposure of neuroblastoma cell
cultures to just 4 h OGD (OGD4h) also induced a statistically
significant increase in LDH release (5.48 ± 0.68%, mean ±
SEM) when compared with control of 4 h reperfusion (C)
(1.38 ± 0.20%), which is about 45% higher than that induced
by IR. This means that, during the OGD treatment, neurons
suffered cellular membrane damage, which is partially repaired
during reperfusion, parallel to a reduction in cell viability loss
of about 30% during the IR condition. The presence of some
nitrones 4 during this period reversed the necrotic death in a
concentration-dependent manner (Figure 3A). The neuro-
protective effects of nitrones, at concentrations from 1 to 500
μM, on necrotic cell death were assayed by adding them at the
beginning of the reperfusion period. Their effect was compared
with the neuroprotective effect of NAC, from 1 to 500 μM
doses, showing a decrease in LDH release in a dose-dependent
manner, having then a significant neuroprotective effect at
concentrations between 10 and 500 μM (ranging from 59 to
100% of maximal reduction) (Figure 3A).
The addition of 10−500 μM nitrone 4e produced a
reduction of necrotic cell death, in the same range as NAC
(from 55 to 100% LDH release inhibition), thus being the
most potent neuroprotective nitrone, followed by nitrone 4a
(52−70% inhibition), indicating that the substitution of Me by
the t-Bu group increases the neuroprotective and antinecrotic
effect. Nitrones 4b−d were also able to reduce LDH release
induced by IR in a dose-dependent manner, although nitrone
4c, nitrone 4b, at 100 μM dose, or nitrone 4d, at 100 and 500
μM concentrations, did not reduce the LDH release, indicating
that, similar to the observed antioxidant and neuroprotective
effects, both nitrones are toxic at these concentrations. In
general, DEOPNs 4a,b have a neuroprotective effect higher
than that of their corresponding DBOPNs, indicating that the
addition of a benzyloxy group, instead of the ethoxy, decreases
their antinecrotic cell death activity.
The observed high antinecrotic cell death capacity of these
nitrones contrasts with their weak capacity to reduce apoptotic
cell death. An increase in caspase-3 activity is correlated with
apoptosis. Thus, to know whether these nitrones reduce
apoptosis induced by experimental ischemia, the caspase-3
activity was measured.
As shown in Figure 3B, the reduction in caspase-3 activity
induced by the nitrones, NAC, and PBN was very small, and
only at high concentrations (100−500 μM), an antiapoptotic
effect was observed. In general, DBOPNs 4f,g seem to be less
antiapoptotic than their analogues DEOPNs, indicating that
the incorporation of a benzyloxy group, instead of an ethoxy
group, decreases not only their antinecrotic but also their
antiapoptotic cell death activity. It is interesting to note that
the introduction of a t-Bu group in nitrone 4e, the best
neuroprotective nitrone in our hands, has an opposite
antinecrotic or antiapoptotic effect. Thus, while this chemical
modification increases the antinecrotic effect, it decreases its
antiapoptotic effect, as shown by comparing these activities
between nitrones 4a and 4e.
To sum up, taken together all of these results of
neuroprotection, antinecrotic, and antiapoptotic activities of
the nitrones described here, we conclude that the mechanism
of their neuroprotective activity might be related to their
antinecrotic actions more than their antiapoptotic activity.
2.3. Antioxidant Assays: ROS Production in Cultures
of SHSY5Y Human Neuroblastoma Cells. It is well
documented that nitrones NXY-059 and PBN have good
antioxidant properties.13,14 To analyze the antioxidant capacity
of nitrones 4 and explore whether ROS could be involved in
their neuroprotective actions, ex vivo experiments were carried
out, following the usual protocols (Supporting Information), to
evaluate the effect of these nitrones on ROS production in
cultures of SHSY5Y human neuroblastoma cells, under oxygen
glucose deprivation (OGD) conditions, using PBN, NAC, and
Table 1. Neuroprotective Effects of Nitrones 4a−g on the
Cell Viability Decrease Induced by Oxygen−Glucose
Deprivation (OGD) and Reperfusion in SHSY5Y
Neuroblastoma Cellsa
aData are given as mean ± standard error of the mean (SEM).
Statistical differences against PBN or compound 4e were determined
by applying a one-way analysis of variance (ANOVA) test. Differences
were considered to be statistically significant when P ≤ 0.05. EC50’s
were calculated from data obtained from three experiments made in
triplicate on cells from four different cultures. ns: nonsignificant; *, P
< 0.05; **, P < 0.01; ***, P < 0.001; compared with the basal value.
Figure 2. EC50 values of the neuroprotective effect of DEOPNs 4a−e
and DBOPNs 4f,g.
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CCh for comparative purposes and sodium nitroprusside
(SNP) as the positive control.
To address this issue, we monitored superoxide production
by a fluorimetric assay. SHSY5Y neuroblastoma cells in the
culture had a basal superoxide production rate of 0.76 ± 0.072
AFU/min × 2 × 105 cells (n = 10; Figure 4A). OGD (3 h) and
IR (3 h reperfusion after 3 h OGD) caused an increase in the
rate of O2
•− production (Figure 4A), reaching values of 1.73 ±
0.18 and 2.59 ± 0.278 AFU/min × 2 × 105 cells (n = 10),
respectively, values similar to that obtained for 3 h of cell
treatment with 2 mM SNP. Nitrone 4e reduced IR-induced
superoxide production in a dose-dependent manner, resulting
in the 100% inhibition at 1 mM concentration (0.82 ± 0.091
AFU/min × 2 × 105 cells; P < 0.001, ANOVA test) (Figure
4A, inset). Results of Figure 4B show that all of the nitrones
were able to reduce ROS levels measured by a dihydroethi-
dium (DHE) probe. After reperfusion (IR) for 3 h and 3 h
under OGD conditions, ROS levels were significantly
increased 2.5-fold with respect to the control and also
significantly higher than in the OGD conditions alone.
Nitrones showed antioxidant power, ranging from a reduction
of about 30−35% for nitrones 4a and 4c, 60−65% for nitrones
4d and 4f (0.1 mM concentrations), and 40−45% for nitrones
4a,b,d or 70−80% for the most potent antioxidant nitrones 4e
and 4f (at 1 mM concentration). In the case of nitrones 4b and
4d, an inverse relationship exists between the nitrone
concentration and antioxidant activity, indicating thus a
possible toxic effect at concentrations higher than 1 mM.
These results confirm that the antioxidant power of the
nitrones tested here translates into their neuroprotective
activity (see below). Interestingly, nitrone 4f is one of the
most potent antioxidant nitrones in the ex vivo analysis,
especially at a high, 1 mM, concentration, showing ROS (%)
reduced values higher than those observed for PBN, NAC, and
CCh (Figure 4B).
We observed that, among DEOPNs 4a−e, nitrones 4d and
4e are the most potent antioxidants. The incorporation of
benzyl or t-butyl motifs, instead of the methyl group, seems to
increase the antioxidant capacity of these nitrones, and the α-
substitution on nitrone 4b by a methyl group significantly
increases its antioxidant capacity, more strongly in the resulting
(R)-enantiomer 4c than in the (S)-enantiomer 4d. However,
both nitrones 4b and the (S)-enantiomer 4d show less
antioxidant activity at 1 mM than at 0.1 mM concentrations,
which is possibly due to the fact that at high concentrations
both nitrones are more toxic than (R)-enantiomer nitrone 4c.
By comparing DEOPNs 4a and 4b with the corresponding
DBOPNs 4f and 4g, we conclude that nitrone 4f is 2-fold more
potent than nitrone 4a (R = Me) (P < 0.01) but that nitrone
4b has a neuroprotective potency very similar to that of nitrone
4g (R = Bn) (nonstatistically significant).
Very interestingly, the most potent neuroprotective nitrone
4e shows high values for the inhibition of the lipid
peroxidation (LP) (62%), inhibition of the 5-lipoxygenase
(LOX) (45%), and lipophilicity (Clog P = 2.04) (Table 2).
These results are in good agreement with its capacity to inhibit
superoxide production shown in the ex vivo experiments
(about 100% at 1 mM; Figure 4A,B). Thus, the antioxidant
Figure 3. Effect of nitrones on (A) lactate dehydrogenase (LDH) release or (B) caspase-3 activity in SHY5Y human neuroblastoma cell cultures
exposed to oxygen−glucose deprivation (OGD). The bar chart shows the percentage of LDH release at 24 h of recovery after (A) 3 h OGD or (B)
caspase-3 activity (AFU/μg protein/h), either untreated (R24h) or treated with different concentrations (μM) of nitrones 4a−g or NAC and PBN.
The value induced by OGD at 3 h without the recovery period (OGD3h) is also indicated. LDH release corresponding to R24h cells exposed to 3
h OGD and 24 h of reperfusion (R24h) (3.78 ± 0.48%) was considered as 100%. The values represent the average of three independent
experiments (mean ± SEM) at *P < 0.05, **P < 0.01, and ***P < 0.001 vs R24h by one-way analysis of variance followed by Holm−Sidak’s post-
test, when analysis of variance was significant. Statistical significances above the R24h value are not shown.
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properties of these nitrones could be strongly involved in their
neuroprotective effects.
3. CONCLUSIONS
We report herein the synthesis and neuroprotective properties
of some N-substituted C-dialkoxyphosphorylated nitrones 4,
easily available in good yields from commercial starting
materials. Regarding the neuroprotection analysis, DEOPNs
t-butyl nitrone 4b and benzyl nitrone 4e have been identified
as good neuroprotective nitrones, although in the case of
nitrone 4b, no clear trends have been observed to correlate
these results with its antioxidant capacity. The replacement of a
methyl group with a t-butyl or benzyl group improves the
neuroprotective power of the corresponding nitrone. Similarly,
the replacement of the benzyl with a methyl group reduces the
neuroprotective capacity, resulting in less-potent nitrones 4c
and 4d, where we have observed that the (S)-enantiomer is
4.2-fold more potent than the (R)-enantiomer. To sum up,
DEOPN 4e has been identified as the most potent neuro-
protective, antinecrotic agent investigated here, showing the
capacity to inhibit LP and decrease superoxide levels in
neuronal cultures, and consequently deserves further inves-
tigation. The etiology and origin of stroke, as a complex and
multifactorial disease, is unknown. However, as the oxidative
stress is thought to play a key role, among other factors, we
have tried to explain the observed neuroprotective effect by
nitrone 4e on these grounds but without excluding other
factors and mechanisms being involved.
4. EXPERIMENTAL SECTION
4.1. Chemistry: General Methods. 1H NMR spectra
were recorded in CDCl3 on the following spectrometers:
Varian Mercury-300 and Bruker Avance III (600 MHz) with
tetramethylsilane as the internal standard. 13C NMR spectra
were recorded for CDCl3 solution on the Varian Mercur-300
machine at 75.5 MHz, whereas for DMSO solution on Bruker
Avance III at 151.0 MHz. IR spectra were recorded on an
Infinity MI-60 FT-IR spectrometer. Melting points were
determined on Boetius apparatus and were uncorrected.
Elemental analyses were carried out on a PerkinElmer PE
2400 CHNS analyzer. The following adsorbents were used:
column chromatography, Merck silica gel 60 (70−230 mesh);
analytical TLC, Merck TLC plastic sheets silica gel 60 F254.
4.2. General Method for the Synthesis of Nitrones. To
a stirred solution of oxalyl chloride (0.210 mL, 2.48 mmol) in
CH2Cl2 (5 mL) under an argon atmosphere, DMSO (0.360
mL, 5.15 mmol) dissolved in CH2Cl2 (1.5 mL) was added
dropwise at −60 °C. After 30 min, a solution of the
appropriate dialkoxy hydroxymethylphosphonate 5 or 6 (2.0
mmol) in CH2Cl2 (2 mL) was added followed by triethylamine
(0.850 mL, 6.00 mmol) and the respective alkylhydroxylamine
(2.0 mmol). The cooling bath was removed, and saturated
aqueous NaHCO3 (10 mL) was added when the temperature
of the reaction mixture reached 0 °C. The aqueous layer was
extracted with CH2Cl2 (3 × 5 mL), and the organic phases
combined were washed with brine, dried (MgSO4), and
concentrated to yield the crude nitrone 4, which was purified
by column chromatography using a chloroform−MeOH
mixture (50:1). More details about these methods are briefly
described in the Supporting Information.
4.3. Antioxidant “in Vitro” Assays. In vitro inhibition of
linoleic acid peroxidation and soybean-lipoxygenase was
evaluated spectrophotometrically as reported previously.15
These methods are briefly described in the Supporting
Information.
Figure 4. Inhibitory effects of nitrones 4 on ROS (superoxide)
production in SHSY5Y human neuroblastoma cell cultures exposed to
OGD 3 and 3 h reperfusion (IR). (A) Rate of experimental ischemia
and reperfusion-induced superoxide production. ROS production was
determined as indicated in Methods. The slopes of the lines fitting the
fluorescence intensity changes (an index of the rate of superoxide
production) were individually calculated and averaged. The mean
slope values were used to generate a theoretical line using the
following equation: y = ax. The figure represents the generated lines
for superoxide production in untreated cells and in the presence of
OGD, IR, and SNP as a positive control. The inset represents the
effect of 0.1 and 1 mM nitrone 4e on superoxide production induced
by experimental ischemia (OGD + reperfusion; IR). (B) Effect of
nitrones 4 on the ROS levels induced by IR. The bars show the
percentage of ROS obtained by the IR treatment in the absence and
presence of the indicated concentrations of nitrones, PBN, NAC, and
CCh. The data represent the mean ± SEM of three determinations,
each performed in triplicate (n = 9). The statistics compare the effect
of the OGD or IR over their respective controls at 3 and 3 + 3 h,
respectively (*red), or the effect of the different compounds on the IR
condition (*black) to ***P < 0.001 (one-way ANOVA, followed by
Holm−Sidak analysis as a post hoc test). SNP (1−2 mM) was used as
a positive control of ROS formation.
Table 2. Clog P and in Vitro Inhibition of LOX and LP
Antioxidant Activity of Nitrone 4e and the Standardsa
compounds Clog P LOXa (%) LPa (%)
4e 2.04 45 62
NDGA  91 
Trolox   88
aNitrone and standards tested at 100 μM; values are means ±
standard deviation of three or four different determinations. , no
activity under the experimental conditions. Means within each column
differ significantly (P < 0.05).
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4.4. Neuroprotection Assays. 4.4.1. Neuroblastoma Cell
Cultures. The human neuroblastoma cell line SHSY5Y was
cultured in Dulbecco’s modified Eagle’s medium: Ham’s F12
medium as described in ref 16. For assays, SHSY5Y cells were
subcultured in 96- or 48-well plates at a seeding density of
(0.50−1) or (2−2.5) × 105 cells per well, respectively. When
the SHSY5Y cells reached 80% confluence, the medium was
replaced with fresh medium containing 0.01 μM to 10 mM
compound concentrations or PBS in the controls, as indicated
in each assay.
4.4.2. Neuroblastoma Cell Culture Exposure to Oxygen−
Glucose Deprivation (OGD). Neuroblastoma cell cultures
were exposed to OGD so as to induce cellular damage
(experimental ischemia). Cultured cells were washed and
placed in glucose-free Dulbecco’s medium and maintained in
an anaerobic chamber containing a gas mixture of 95% N2/5%
CO2 and humidified at 37 °C, as described in ref 17. Cells were
exposed to OGD for a period of 3−4 h (OGD4h), as indicated.
Then, the culture medium was replaced with oxygenated
serum-free medium and cells were placed and maintained in
the normoxic incubator for 24 h for recovery (R24h). Nitrones
were analyzed independently three to five times with different
batches of cultures, and each experiment was run in triplicate.
4.4.3. Assessment of Cell Viability. Measurements of cell
viability in human SHSY5Y neuroblastoma cells (about (0.75−
1) × 105 cells/well) were carried out in 96-well culture plates
by the XTT methods, as described in ref 17.17
4.4.4. Measurement of LDH Activity. For these assays,
cultured neuroblastoma cells grown in 96-well culture dishes at
a density of 1.5 × 105 cells/well were used. LDH activity was
measured as the rate of decrease of the absorbance at 340 nm,
resulting from the oxidation of NADH to NAD+ as
described.17 Data are given as the percentage of LDH release
with respect to the total LDH content (LDH in the culture
medium and LDH inside the cells).
4.4.5. Analysis of Caspase-3 Activity. For these assays,
cultured neuroblastoma cells grown in 48-well culture dishes,
at a density of 2.5 × 105 cells/well, were used. After OGD
treatment, cells were treated with different nitrones or
indicated positive controls at 1−500 μM concentrations and
subjected to 24 h reperfusion. Attached cells were lysed at 4 °C
in a lysis medium containing 5 mM Tris/HCl (pH 8.0), 20
mM ethylenediaminetetraacetic acid, and 0.5% Triton X-100
and centrifuged at 13 000g for 10 min. The activity of caspase-
3 was measured using the fluorogenic substrate peptide
DEVD-amc (66081; BD Biosciences PharMingen), as
described in refs17, 18. Proteins were measured by the
Bradford assay. Results were expressed as arbitrary fluores-
cence units [(AFU)/μg protein/h].
4.4.6. Measurement of ROS Formation. SHSY5Y human
neuroblastoma cells (2 × 105 cells/well) were exposed to OGD
for a period of 3 h (OGD3h). At the end of the OGD period,
the culture medium was replaced with oxygenated Dulbecco’s
modified Eagle’s medium containing glucose and 10% fetal calf
serum. Cells were treated in the absence (controls) or presence
of indicated concentrations of nitrones or different known
neuroprotective agents and maintained at 37 °C in a normoxic
incubator for 3 h for recovery. At the end of this period, 20 μM
DHE (HEt; Molecular Probes) was added and fluorescence
was recorded every 15−30 s during a 15 min period, using an
excitation filter of 535 nm and an emission filter of 635 nm in a
spectrofluorimeter (Bio-Tek FL 600) as previously de-
scribed.18,19 Linear regression of fluorescence data [expressed
as arbitrary fluorescence units (AFU)] was calculated for each
condition, and the slopes (a) of the best fitting lines (y = ax)
were considered as an index of O2
•− production. SNP was used
as a positive control of superoxide production.19
4.5. Statistical Analysis. Data were expressed as mean ±
SEM of results obtained from at least three independent
experiments from different cultures, each of which was
performed in triplicate. Statistical comparisons between the
different experimental conditions were performed using one-
way analysis of variance (ANOVA), followed by Holm−Sidak’s
post-test when the analysis of variance was significant. A P-
value <0.05 was considered statistically significant. Fit curves
for EC50 determinations were performed according to the
program of SigmaPlot v.11 (Systat Software INC., 2012).
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